Tongfang Kontafarma Holdings Limited (1312.HK)
HKD 0.03
(3.57%)
HKD 0.03
(3.57%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 333.82 Million HKD | -43.49% |
| 2022 | 590.72 Million HKD | -18.96% |
| 2021 | 728.95 Million HKD | -2.97% |
| 2020 | 751.29 Million HKD | -16.34% |
| 2019 | 898.03 Million HKD | 63.15% |
| 2018 | 550.42 Million HKD | -31.91% |
| 2017 | 808.41 Million HKD | -25.11% |
| 2016 | 1.07 Billion HKD | 38.84% |
| 2015 | 777.45 Million HKD | 75.67% |
| 2014 | 442.55 Million HKD | 368.36% |
| 2013 | 94.49 Million HKD | -7.36% |
| 2012 | 101.99 Million HKD | -16.82% |
| 2011 | 122.61 Million HKD | 18.78% |
| 2010 | 103.22 Million HKD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 284.64 Million HKD | 0.0% |
| 2023 Q1 | 319.41 Million HKD | -45.93% |
| 2023 Q3 | 267.68 Million HKD | -29.33% |
| 2023 Q2 | 378.77 Million HKD | 18.59% |
| 2023 Q4 | 333.82 Million HKD | 24.71% |
| 2023 FY | 333.82 Million HKD | -43.49% |
| 2022 Q2 | 585.98 Million HKD | 13.88% |
| 2022 FY | 590.72 Million HKD | -18.96% |
| 2022 Q4 | 590.72 Million HKD | 12.11% |
| 2022 Q3 | 526.91 Million HKD | -10.08% |
| 2022 Q1 | 514.55 Million HKD | -29.41% |
| 2021 Q2 | 758.17 Million HKD | 5.41% |
| 2021 Q1 | 719.28 Million HKD | -4.26% |
| 2021 Q4 | 728.95 Million HKD | 12.31% |
| 2021 FY | 728.95 Million HKD | -2.97% |
| 2021 Q3 | 649.07 Million HKD | -14.39% |
| 2020 Q2 | 1.07 Billion HKD | 8.27% |
| 2020 FY | 751.29 Million HKD | -16.34% |
| 2020 Q3 | 665.56 Million HKD | -37.88% |
| 2020 Q4 | 751.29 Million HKD | 12.88% |
| 2020 Q1 | 989.5 Million HKD | 10.19% |
| 2019 Q3 | 924.62 Million HKD | -6.76% |
| 2019 Q2 | 991.66 Million HKD | 5.47% |
| 2019 Q1 | 940.24 Million HKD | 70.82% |
| 2019 Q4 | 898.03 Million HKD | -2.88% |
| 2019 FY | 898.03 Million HKD | 63.15% |
| 2018 Q4 | 550.42 Million HKD | 0.18% |
| 2018 Q2 | 661.43 Million HKD | 0.15% |
| 2018 FY | 550.42 Million HKD | -31.91% |
| 2018 Q1 | 660.42 Million HKD | -18.31% |
| 2018 Q3 | 549.41 Million HKD | -16.94% |
| 2017 Q1 | 954.34 Million HKD | -11.59% |
| 2017 Q4 | 808.41 Million HKD | 0.19% |
| 2017 Q3 | 806.91 Million HKD | -15.61% |
| 2017 FY | 808.41 Million HKD | -25.11% |
| 2017 Q2 | 956.15 Million HKD | 0.19% |
| 2016 Q2 | 780 Million HKD | 0.0% |
| 2016 FY | 1.07 Billion HKD | 38.84% |
| 2016 Q3 | 1.07 Billion HKD | 38.39% |
| 2016 Q1 | 780 Million HKD | 0.33% |
| 2016 Q4 | 1.07 Billion HKD | 0.0% |
| 2015 Q1 | 1.08 Billion HKD | 145.81% |
| 2015 Q4 | 777.45 Million HKD | 0.0% |
| 2015 Q3 | 777.45 Million HKD | -28.53% |
| 2015 Q2 | 1.08 Billion HKD | 0.0% |
| 2015 FY | 777.45 Million HKD | 75.67% |
| 2014 Q4 | 442.55 Million HKD | -0.02% |
| 2014 Q3 | 442.62 Million HKD | 47.81% |
| 2014 Q1 | 299.54 Million HKD | 217.01% |
| 2014 FY | 442.55 Million HKD | 368.36% |
| 2014 Q2 | 299.45 Million HKD | -0.03% |
| 2013 Q2 | 98.13 Million HKD | 0.0% |
| 2013 Q4 | 94.49 Million HKD | -0.1% |
| 2013 Q3 | 94.58 Million HKD | -3.62% |
| 2013 FY | 94.49 Million HKD | -7.36% |
| 2013 Q1 | 98.13 Million HKD | -3.78% |
| 2012 Q3 | - HKD | -100.0% |
| 2012 Q2 | 111.87 Million HKD | 0.0% |
| 2012 Q4 | 101.99 Million HKD | 0.0% |
| 2012 FY | 101.99 Million HKD | -16.82% |
| 2011 Q4 | 122.61 Million HKD | 0.0% |
| 2011 FY | 122.61 Million HKD | 18.78% |
| 2010 FY | 103.22 Million HKD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -4801.954% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 90.194% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | -177.239% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | 27.579% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -68446.817% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | -63.527% |
| Essex Bio-Technology Limited | 294.02 Million HKD | -13.537% |
| PuraPharm Corporation Limited | 424.77 Million HKD | 21.411% |
| SSY Group Limited | 3.37 Billion HKD | 90.106% |
| JBM (Healthcare) Limited | 133.4 Million HKD | -150.229% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | 55.453% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 99.611% |